• BHUPINDER KAUR Department of Pharmaceutics, University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab, India https://orcid.org/0000-0002-8423-6613
  • NISHANT THAKUR Department of Pharmaceutics, University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab, India https://orcid.org/0000-0003-2160-1836
  • MANISH GOSWAMI Saraswati Group of Colleges, Gharuan, Mohali, Punjab, India




Microneedles, 3D printing, Dental SG, Porcine skin, Permeation, Ɣ-Oryzanol, Transdermal patches


Objective: This study's goals were to develop a minimally invasive array of biocompatible polymeric solid microneedles and formulate a transdermal patch of drug Ɣ-Oryzanol as per poke and patch technology.

Methods: Scanning electron microscopy was used to analyse the morphology of the solid microneedle arrays, which were created using a stereolithography (SLA) printer with high-resolution capabilities (25 and 140 microns for the z and x axes, respectively). Transdermal Patches of Ɣ-Oryzanol were formulated and evaluated for various characterization parameters. Further, the produced microneedle-transdermal drug delivery system of Ɣ-Oryzanol was examined for microneedle insertion skin and permeation of the drug across the porcine skin.

Results: Solid microneedle arrays were manufactured using biocompatible Class I Dental SG resin having dimensions of 600 µm height and 300 µm width with tip diameters of 30 µm and 1.85 mm interspacing (Distance from tip to tip) and they were strong enough to penetrate porcine skin to a depth of 381.356 µm crossing the stratum corneum layer without causing any structural changes. Transdermal patches containing Ɣ-Oryzanol were formulated using different ratios of HPMC: Eudragit E-100. Good, consistent, and transparent films were formulated when the thickness of the film ranges between 0.516±0.25-0.628±0.21 mm, average weights ranged from 168.23±2.61to171.22±1.25(10/cm2), folding endurance ranged in between 10 folds to 12 folds for all the formulations with tensile strength lie between the 0.365 kg/mm2 to 0.465 kg/mm2. All the formulations showed good drug content between 99.3±0.06%-90.4±1.64% with 100% flat surfaces. Moisture content was found in the range of 2.012±0.013 to 4.213±0.031. Drug permeation studies reveal that compound Ɣ-Oryzanol transdermal patches didn’t show significant permeation across porcine skin (4.802.25 g/cm2) without piercing with microneedles while after poking skin using microneedles (74.502.35 g/cm2) drug showed good penetration properties. It was found that the amount of drug delivered increased to 44.251.57 g/cm2 at 2 min, which was 14.502.35 g/cm2 at 1 min to 4 min 74.502.35 g/cm2.

Conclusion: Successful preparation of the Microneedle-Transdermal drug delivery system of Ɣ-Oryzanol and their evaluation indicated that the quality and consistency of the formulated preparation were excellent. With advantages in terms of lowered dose frequency, better patient compliance, and bioavailability, this may find use in the therapeutic field.


Download data is not yet available.


Hao Y, Li W, Zhou XL, Yang F, Qian ZY. Microneedles-based transdermal drug delivery systems: a review. J Biomed Nanotechnol. 2017;13(12):1581-97. doi: 10.1166/jbn.2017.2474, PMID 29490749.

Anantrao JH, Nath PA, Nivrutti PR. Drug penetration enhancement techniques in transdermal drug delivery system: a review. J Pharm Res Int. 2021;33(19B):46-61. doi: 10.9734/jpri/2021/v33i19B31337.

Nagadev C, Rao MDS, Venkatesh P, Hepcykalarani D, Prema R. A review on transdermal drug delivery systems. Asian J Res Pharm Sci. 2020;10(2):109-14. doi: 10.5958/2231-5659.2020.00021.1.

Gaikwad AK. Transdermal drug delivery system: formulation aspects and evaluation. Compr J PharmSci. 2013;1(1):1-10.

Mali AD, Bathe R, Patil M. An updated review on transdermal drug delivery systems. Int J of Adv in Sci Res. 2015;1(6):244-5. doi: 10.7439/ijasr.v1i6.2243.

Sarkar P, Das S, Majee SB. Biphasic dissolution model: a novel strategy for developing discriminatory in vivo predictive dissolution model for BCS class ii drugs. Int J Pharm Pharm Sci. 2022;14(4):20-7. doi: 10.22159/ijpps.2022v14i4.44042.

Ghosh M. Review on recent trends in rice bran oil processing. J Amer Oil Chem Soc. 2007;84(4):315-24. doi: 10.1007/s11746-007-1047-3.

Filho Acva GMIF, Duarte SF, Lima-Neto ABM. Gamma-oryzanol has equivalent efficacy as a lipid-lowering agent compared to fibrate and statin in two dyslipidemia mice models. Int J Pharm Pharm Sci. 2014;6(11):61-4.

Manoj VR, Manoj H. Review on transdermal microneedle-based drug delivery. Asian J Pharm Clin Res. 2019;12(1):18-29. doi: 10.22159/ajpcr.2019.v12i1.27434.

Kalona PA, Sundaresan U, Kasinathan ID, Muthiah C. Studies on red rice bran and its health benefits of food application-a review. Int J Pharm Res. 2020;14(3):1-6.

Sen S, Chakraborty R, Kalita P. Rice–not just a staple food: A comprehensive review on its phytochemicals and therapeutic potential. Trends Food Sci Technol. 2020;97:265-85. doi: 10.1016/j.tifs.2020.01.022.

Banerjee N, Chatterjee S, Bhattacharjee S, Bhattacharya BDES, Mukherjee S. Rice bran oil consumption: cardiovascular disease and obesity risk reduction. Drug Invent Today. 2018;10(1):402-7.

Panda A, Matadh VA, Suresh S, Shivakumar HN, Murthy SN. Non-dermal applications of microneedle drug delivery systems. Drug Deliv Transl Res. 2022;12(1):67-78. doi: 10.1007/s13346-021-00922-9, PMID 33629222.

Agrawal S, Gandhi SN, Gurjar P, Saraswathy N. Microneedles: an advancement to transdermal drug delivery system approach. J App Pharm Sci. 2020;10(3):149-59. doi: 10.7324/JAPS.2020.103019.

Dukare MV, Saudagar RB. Needle-free injection system. Int J Curr Pharm Sci. 2018;10(2):17-24. doi: 10.22159/ ijcpr.2018v10i2.25885.

Vora LK, Moffatt K, Tekko IA, Paredes AJ, Volpe Zanutto F, Mishra D. Microneedle array systems for long-acting drug delivery. Eur J Pharm Biopharm. 2021;159:44-76. doi: 10.1016/j.ejpb.2020.12.006, PMID 33359666.

SR, DS, IH. Microneedle drug delivery system-overview. Int J Res Pharm Sci. 2011;109:1249-58.

Zong Q, Guo R, Dong N, Ling G, Zhang P. Design and development of insulin microneedles for diabetes treatment. Drug Deliv Transl Res. 2022;12(5):973-80. doi: 10.1007/s13346-021-00981-y, PMID 33851362.

Meng F, Hasan A, Mahdi Nejadi Babadaei M, Hashemi Kani P, Jouya Talaei A, Sharifi M, Cai T, Falahati M, Cai Y. Polymeric-based microneedle arrays as potential platforms in the development of drugs delivery systems. J Adv Res. 2020;26:137-47.

Damiri F, Kommineni N, Ebhodaghe SO, Bulusu R, Jyothi VGSS, Sayed AA. Microneedle-based natural polysaccharide for drug delivery systems (DDS): progress and challenges. Pharmaceuticals (Basel). 2022;15(2):190. doi: 10.3390/ph15020190, PMID 35215302.

Sabri AH, Ogilvie J, hamid AK, Shpadaruk V, McKenna J, Segal J, Scurr DJ, Marlow M. Expanding the applications of microneedles in dermatology. Eur J Pharm Biopharm. 2019; 140:121-40.

He X, Sun J, Zhuang J, Xu H, Liu Y, Wu D. Microneedle system for transdermal drug and vaccine delivery: devices, safety, and prospects. Dose-Response. 2019 Oct 14;17(4):1559325819878585. doi: 10.1177/ 1559325819878585, PMID 31662709.

Parhi R, N DS. Review of microneedle-based transdermal drug delivery systems. PCI- Approved-IJPSN 2019;12(3):4511-23. doi: 10.37285/ijpsn.2019.12.3.1.

Sharma C, Thakur N, Kaur B, Goswami M. Investigating effects of permeation enhancers on percutaneous absorption of loxapine succinate. Int J Appl Pharm. 2022;14(4):158-62. doi: 10.22159/ijap.2022v14i4.44896.

Lahiji SF, Dangol M, Jung H. A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery. Sci Rep. 2015;5:7914. doi: 10.1038/srep07914, PMID 25604728.

Dharadhar S, Majumdar A, Dhoble S, Patravale V. Microneedles for transdermal drug delivery: a systematic review. Drug Dev Ind Pharm. 2019 Feb;45(2):188-201. doi: 10.1080/03639045.2018.1539497, PMID 30348022.

Prajapati ST, Patel CG, Patel CN. Formulation and evaluation of transdermal patch of repaglinide. ISRN Pharm. 2011;2011:651909. doi: 10.5402/2011/651909, PMID 22389856.

Kozuka C, Kaname T, Shimizu Okabe C, Takayama C, Tsutsui M, Matsushita M. Impact of brown rice-specific γ-oryzanolon epigenetic modulation of dopamine D2 receptors in brain striatum in high-fat-diet-induced obesity in mice. Diabetologia. 2017 Aug;60(8):1502-11. doi: 10.1007/s00125-017-4305-4, PMID 28528402.

Ramadon D, McCrudden MTC, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug Deliv Transl Res. 2022 Apr;12(4):758-91. doi: 10.1007/s13346-021-00909-6, PMID 33474709.

Xu J, Xu D, Xuan X, He H. Advances of microneedles in biomedical applications. Molecules. 2021 Sep 29;26(19):5912. doi: 10.3390/molecules26195912, PMID 34641460.

Damiri F, Kommineni N, Ebhodaghe SO, Bulusu R, Jyothi VGSS, Sayed AA. Microneedle-based natural polysaccharide for drug delivery systems (DDS): progress and challenges. Pharmaceuticals (Basel). 2022 Feb 3;15(2):190. doi: 10.3390/ph15020190, PMID 35215302.

Das A, Ahmed AB. Formulation and evaluation of transdermal patch of indomethacin containing patchouli oil as a natural penetration enhancer. Asian J Pharm Clin Res. 2017 Nov 1;10(11):320-5. doi: 10.22159/ajpcr.2017.v10i11.20926.

Chaiyasan W, Srinivas SP, Niamprem P, Tiyaboonchai W. Penetration of hydrophilic sulforhodamine B across the porcine cornea ex-vivo. Int J Appl Pharm. 2018;10(6):94-102. doi: 10.22159/ijap.2018v10i6.28505.

Thakur N, Kaur B, Goswami M, Sharma C. Compatibility studies of the thiocolchicoside with Eudragit RLPO, Eudragit E100 and Eudragit L100 using thermal and non-thermal methods. Drug Comb Ther. 2022;4(1):1. doi: 10.53388/DCT2021100301.

Sharma C, Thakur N, Kaur B, Goswami M. Transdermal patches: state of the art. Int J Drug Deliv Technol. 2020;10(3):414-20. doi: 10.25258/ijddt.10.3.19.

Zhan X, Mao Z, Chen S, Chen S, Wang L. Formulation and evaluation of transdermal drug-delivery system of isosorbide dinitrate. Braz J Pharm Sci. 2015;51(2):373-82. doi: 10.1590/S1984-82502015000200015.

Patel KN, Patel HK, Patel VA. Formulation and characterization of drug in adhesive transdermal patches of diclofenac acid. Int J Pharm Pharm Sci. 2012;4(1):296-9.

Milewski M, Yerramreddy TR, Ghosh P, Crooks PA, Stinchcomb AL. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. J Control Release. 2010;146(1):37-44. doi: 10.1016/j.jconrel.2010.05.034, PMID 20678989.



How to Cite

KAUR, B., THAKUR, N., & GOSWAMI, M. (2022). EVALUATING THE IMPACT OF SOLID MICRONEEDLES ON THE TRANSDERMAL DRUG DELIVERY SYSTEM FOR Ɣ-ORYZANOL. International Journal of Applied Pharmaceutics, 14(6), 34–41. https://doi.org/10.22159/ijap.2022v14i6.46233



Original Article(s)